Your Part Is Getting Wider: What That Actually Means

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.
Published on mdhair.com — Hormonal & Life Stage Hair Loss Series

You saw it in a photograph. Or in a lift, under that particular overhead lighting that seems designed to be unkind. Or you looked down at the top of your own head in a hand mirror for the first time in years, and the line where your hair separates was not a line anymore. It was a channel. Pale scalp, clearly visible, running further back than you remember it ever running.

And then you did what everybody does: you parted your hair on the other side, checked again, told yourself it was the light, and did not mention it to anyone.

I want to take that observation seriously, because it deserves to be taken seriously. A widening part is not a trivial cosmetic complaint. It is often the earliest reliable sign of female pattern hair loss — and it is early enough that noticing it is genuinely useful rather than merely distressing. It is also, importantly, not the only thing that widens a part. Three different processes can produce the same appearance, and they call for three different responses.

So: what the part line actually measures, why it is the first place change shows, how to photograph it so you are comparing like with like, and how to tell which of the three things you are looking at.

Why the Part Is the First Place You Notice

Hair does not cover the scalp the way paint covers a wall. It covers it the way a forest covers ground — by overlap, at an angle, with each hair shading what is beneath it. Coverage is a function of three things: how many follicles are producing hair, how thick each hair is, and how the hairs lie.

The part line removes the overlap. It is the one place on your head where hair is deliberately pulled away from the midline in both directions, leaving scalp exposed by design. That makes it the most sensitive optical detector of density you own. A small reduction in the number and calibre of hairs emerging along that line translates immediately into a wider visible band of skin — while the same reduction elsewhere on the scalp is still being hidden by the hairs lying over it.

Which is why the part widens before anything else looks wrong. Your ponytail may still feel adequate. Your hairline may be untouched. And the part is already reporting.

The Underlying Process: Miniaturization

The reason a part widens in pattern hair loss is not, in the early stages, that follicles have disappeared. It is that they have shrunk.

In genetically susceptible follicles, testosterone converted locally by 5-alpha-reductase into dihydrotestosterone (DHT) binds androgen receptors in the dermal papilla and progressively shortens the anagen — growth — phase. Each cycle the follicle spends less time growing. A shorter growth phase produces a shorter hair, and the follicle itself involutes, producing a narrower shaft. Repeat over ten or fifteen cycles and a terminal hair of 60–90 micrometres becomes a fine, short, weakly pigmented hair that contributes almost nothing to coverage (Whiting, 1993; Sawaya & Price, 1997).

Two things follow from this that matter enormously to how you should think about your part line.

First, the follicle is still there. Miniaturization is a change in output, not an absence of tissue. That is the entire basis for the hope in this article: a miniaturized follicle remains a living, responsive structure, and follicles that have been miniaturized can enlarge again when their environment changes. What cannot be recovered is a follicle that has been replaced by fibrous tissue — and the gap between those two states is measured in years, which is why early is the operative word.

Second, the visual change is non-linear. Because coverage depends on shaft diameter and diameter falls gradually, nothing appears to happen for a long time and then a great deal appears to happen at once. Patients describe pattern loss as sudden. It is not sudden. It crossed a visual threshold suddenly.

The Ludwig Pattern: What Female Pattern Loss Looks Like

Female pattern hair loss has a characteristic geography, first classified by Erich Ludwig in 1977 and still the framework in daily clinical use.

  • Ludwig I — perceptible thinning of the crown, with the frontal hairline preserved. This is the widening-part stage.
  • Ludwig II — pronounced rarefaction of the crown; the part is clearly wide and scalp is visible over a broad central area.
  • Ludwig III — the central scalp is nearly denuded, though the frontal fringe typically persists (Ludwig, 1977).

Two features distinguish this from male-pattern recession. The frontal hairline is characteristically retained — women rarely develop the temple recession men do. And the loss is centrifugal from the midline: it is worst along the part and fades laterally, which is precisely why the part is the diagnostic zone.

Elise Olsen described an additional and very common variant: frontal accentuation, in which the widening is greatest at the front of the part and tapers backwards, producing a triangular or "Christmas tree" shape when the hair is parted down the middle (Olsen, 2001). If your part looks like a wedge rather than a stripe, that is a recognised presentation, not something unusual.

The other reliable sign, and the one a dermatologist will look for on dermoscopy, is variability in hair calibre — thick, medium and very fine hairs side by side within the same small area, because the follicles in that area are at different points along the miniaturization path. A scalp thinning from a shed has hairs of uniform thickness. A scalp thinning from pattern loss does not (Rudnicka et al., 2008).

Three Things That Widen a Part — and How to Tell Them Apart

This is the practical core of the article.

1. Pattern hair loss

Looks like: gradual over months to years. Widening concentrated at the part and crown, worst at the front of the part in many women. Back and sides look comparatively normal. Hairs of visibly mixed thickness. Daily shedding often normal — this is the confusing part. Frequently a family history on either side.

What it needs: a decision about time, because it is progressive and the follicle's recoverability is finite.

2. A telogen effluvium — a diffuse shed

Looks like: abrupt onset, usually two to four months after a trigger (childbirth, illness, surgery, rapid weight loss, iron deficiency, thyroid change, a new medication, severe stress). Dramatically increased shedding — handfuls in the shower. And critically, the thinning is everywhere, including the back and sides, so while the part does look wider, so does everything else. Fallen hairs are full length and full thickness, with a small pale club bulb at the root (Grover & Khurana, 2013).

What it needs: its cause found and removed. Labs, not products: full thyroid panel, serum ferritin, vitamin D, medication review.

3. Traction

Looks like: localised to where tension has been applied, not to the midline — most often the frontal and temporal margins, or along the specific line where the hair has been pulled, clipped or tied for years. If you have parted your hair identically in the same place for a decade and the widening is exactly along that line while the rest of the crown looks fine, sustained mechanical tension is a real candidate. Discomfort, tenderness or small bumps after styling point the same way, and a retained fine fringe of hairs at the very margin is a classic clue (Samrao et al., 2011).

What it needs: the tension removed, promptly — traction alopecia is reversible in its early phase and permanent once follicles are replaced by scar tissue.

And the honest complication, the same one that runs through all of this: these coexist. A shed can strip out the terminal hairs that were hiding five years of quiet miniaturization, which is why so many women date the start of their pattern loss to an illness or a pregnancy that merely revealed it.

How to Photograph a Part Properly

If you take one practical thing from this article, make it this. A widening part changes by perhaps one percent a month. Human memory cannot resolve that. A camera can — but only if you remove every variable except your hair.

The protocol I give patients:

  1. Same room, same time of day, same light. Daylight from a window, indirect, no overhead spotlights. Overhead light is the single biggest source of false alarm, because it rakes across the scalp and exaggerates every gap.
  2. No flash. Flash flattens texture and changes apparent density unpredictably between shots.
  3. Dry hair, same product state. Wet or freshly conditioned hair clumps and shows more scalp; a dry, product-free, gently combed baseline is comparable.
  4. Comb the part in exactly the same place every time. Use a landmark you can reproduce — a set distance from a mole, the outer corner of an eyebrow, the centre of the nose. If the part moves, the measurement is meaningless.
  5. Three fixed angles. Straight down at the part from directly above; the crown from behind and above; the frontal hairline from the front. Same three, every time.
  6. Include a scale. Lay a ruler or a coin flat alongside the part. It sounds excessive. It is the difference between an impression and a measurement.
  7. Once a month, on a fixed date. Not weekly — weekly noise will make you miserable and tells you nothing. The first of the month is easy to remember.
  8. Keep them in one album and do not look at them for ninety days. Then compare month one to month four side by side rather than scrolling through the middle.

This costs you four minutes a month and it converts an anxious, unreliable impression into evidence you and your physician can both use. It also protects you in the other direction — a great many women conclude a product has failed at week six, when week six was never going to show anything.

What to Do About It

Get the reversible things off the table first. A widening part in a woman warrants a full thyroid panel, serum ferritin — not just haemoglobin, since the follicle registers iron shortage well before red cell production does (Trost et al., 2006) — and vitamin D. If there are signs of androgen excess elsewhere — irregular cycles, new facial hair, acne — that warrants an endocrine assessment for polycystic ovary syndrome, which is a common and treatable driver of exactly this picture.

Then address the follicular environment, and start sooner than feels necessary. Whatever route you choose, the argument for acting early is not sales pressure; it is the biology in the section above. A miniaturized follicle can enlarge. A fibrosed one cannot. Every intervention in this field — pharmaceutical or drug-free — performs better on follicles that are still producing something than on follicles that stopped years ago.

And see a dermatologist if the picture does not fit. Widening that is patchy rather than diffuse, scalp pain, redness, pustules, persistent scaling, or a smooth shiny area where the follicular openings appear to have vanished are not features of ordinary pattern loss. Those require assessment promptly, because scarring alopecias destroy follicles permanently and the window to intervene is short.

The Bottom Line

A widening part is the earliest place female pattern hair loss becomes visible, because the part is the one location on your scalp where hair is deliberately pulled apart and cannot hide a reduction in density. Underneath it is miniaturization — follicles shrinking rather than dying, producing shorter and finer hairs each cycle under androgen influence.

But confirm the pattern before you accept the diagnosis. Pattern loss is gradual, midline-centred, spares the back and sides, and produces hairs of visibly mixed thickness. A diffuse shed is abrupt, follows a trigger by about three months, thins the whole scalp including the occiput, and sheds full-thickness hair. Traction follows the line where tension was applied.

Photograph it properly — same room, same light, same part, a coin for scale, monthly — because the change is too slow for memory and too consequential to guess at. Get thyroid, ferritin and vitamin D checked. And treat the early stage as the opportunity it is, rather than the alarm it feels like. The follicles along that widening line are still there. That is the whole reason it is worth acting now.

Dr. Susan Lin's Clinical Perspective

"Almost every woman I see for pattern hair loss describes the same moment — a photograph, a mirror, a particular light — and almost every one of them believes it happened suddenly. It did not. It crossed a visual threshold suddenly, after years of change too gradual to register. That is why I care so much about photographs taken to a protocol: they move the conversation from impression to evidence, and they cut in both directions, protecting patients from false alarm as often as from false reassurance. The clinical point I most want understood is that a widening part is early. Early is good news. A miniaturized follicle is a living follicle with a responsive dermal papilla, and the distance between miniaturized and permanently fibrosed is measured in years — but it is measured, and it only runs one way."

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: Why Shaft Diameter, Not Follicle Count, Decides How Wide Your Part Looks

It is tempting to assume a wider part means you have lost follicles. In early pattern hair loss, mostly you have not. What you have lost is cross-sectional area of hair, and the arithmetic of that loss explains why the change appears so abruptly.

Optical coverage of the scalp depends far more on the width of each fibre than on the number of fibres, because a hair shades a strip of scalp roughly proportional to its diameter. Terminal scalp hairs run about 60–100 micrometres across. A miniaturizing follicle may drop that to 30–40 micrometres, and eventually into the vellus-like range below 30. Halving the diameter roughly halves the strip of scalp that hair conceals — even though the follicle is still present, still cycling, and still counted as a hair on any simple count.

The engine of that narrowing is anagen duration. Whiting's horizontal-section histology showed that androgenetic alopecia is characterised by a progressive increase in the proportion of miniaturized follicles and a rising vellus-to-terminal ratio, rather than by wholesale follicular loss in the early stages (Whiting, 1993). Each cycle the follicle spends less time in growth; a shorter growth phase yields both a shorter hair and, because the hair bulb itself regresses, a thinner one.

Because these follicles enter the process at different times, a thinning scalp shows hairs at every stage simultaneously — the calibre variability that dermoscopy detects and that distinguishes pattern loss from a shed (Rudnicka et al., 2008).

And it explains the non-linear experience. Coverage holds while the average diameter is still high, and then falls away over a short period as a large cohort of follicles crosses below the threshold at which a hair meaningfully shades skin. Nothing accelerated. You simply reached the point where the arithmetic became visible.

Recommended Reading

Pillar pages on mdhair.com:

Related articles in this series:

Our sister site md-factor.com publishes the same ingredient specifications and documentation standards for the wider MD® portfolio.

MD HAIR Product Recommendation

MD Nutri Hair™ — /products/nutri-hair-supplement

I lead with the internal arm here because a widening part is an androgen-and-inflammation story at the follicle, and that story does not begin at the surface of the skin. The best-evidenced thing I can tell you about MD Nutri Hair™ concerns inflammation. Its lilac component is standardized for verbascoside, a plant phenol which in controlled laboratory studies on human dermal papilla cells — the cells at the base of the follicle that govern shaft diameter — reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α, induced cell proliferation, and prevented testosterone-induced cell death. Those are cell studies in a dish, not human trials; the authors state that clinical study is still needed. The verbascoside studied came from Acanthus, not from lilac — the same molecule from a different botanical source, and not a study of our own material (Wisuitiprot et al., 2022). Read more at the lilac & verbascoside science page.

The formula is a once-daily capsule built on a 300 mg proprietary blend, with vitamin B3 as niacinamide, vitamin E as alpha tocopheryl acetate, and D-biotin at 0.05 mg — deliberately a sensible cofactor dose rather than one of the megadoses that can interfere with laboratory immunoassays, which matters when you are about to have thyroid and ferritin drawn. Other ingredients: flaxseed powder, lignan powder, lilac. In the MD Nutri Hair™ 30-day in-office consumer use study (30 subjects, self-reported), 95% saw improved hair appearance, 90% reported better manageability, and 75% reported increased fullness. Individual results vary. As a dietary supplement it is not intended to diagnose, treat, cure, or prevent any disease, and it is not FDA approved — no dietary supplement is. Label warning: keep out of the reach of children. Do not take if you are pregnant or breast feeding. For adults only; one capsule daily.

Alongside it, the topical: MD® Follicle Energizer — /products/follicle-energizer

Internal input and scalp environment are two different jobs, so I pair them rather than substituting one for the other. The Follicle Energizer is a Biotinoyl Tripeptide-1 serum formulated for exactly the zones this article is about — the part line, crown and hairline — with a precision brush applicator so the formula lands on scalp rather than on hair, which is where a serum aimed at the follicular environment has to go to do anything at all. It is drug-free and hormone-free, so it layers with whatever your physician has you on. In a 119-day (17-week) Spincontrol North America study of the two-step topical system — n=24, split-scalp design, self-reported questionnaire, no placebo arm — 71% agreed their hair growth had improved. The report's own assessment states that "the satisfaction rate (concerning the overall efficacy) is not significantly validated." Individual results vary; study on file. Physician-formulated by Dr. Susan F. Lin, M.D. under the MD® mark (U.S. Reg. No. 4,471,494), manufactured in FDA-registered, GMP-compliant facilities in the USA. A cosmetic product, not intended to diagnose, treat, cure, or prevent any disease.

A note on the assessment window: ninety days is the minimum honest period in which to judge anything in this category, mine included — which is precisely why the photograph protocol above matters more than any product on this page.

A note on authenticity: genuine MD HAIR™ and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. We cannot verify the storage, handling, labelling or lot integrity of units bought anywhere else.

Not sure whether what you are seeing is pattern loss, a shed, or traction? Take the MD HAIR Quiz — a structured way to organize the observations above. It is a starting point for reasoning, not a diagnosis.

Learn more about hormonal hair loss at mdhair.com/pages/hormonal-hair-loss

References

  1. Ludwig E. (1977). Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology, 97(3), 247–254. PMID 921894
  2. Olsen EA. (2001). Female pattern hair loss. Journal of the American Academy of Dermatology, 45(3 Suppl), S70–S80. PMID 11511856
  3. Whiting DA. (1993). Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. Journal of the American Academy of Dermatology, 28(5 Pt 1), 755–763. PMID 8496421
  4. Sawaya ME, Price VH. (1997). Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Journal of Investigative Dermatology, 109(3), 296–300. PMID 9284093
  5. Rudnicka L, Olszewska M, Rakowska A, Kowalska-Oledzka E, Slowinska M. (2008). Trichoscopy: a new method for diagnosing hair loss. Journal of Drugs in Dermatology, 7(7), 651–654. PMID 18664157
  6. Grover C, Khurana A. (2013). Telogen effluvium. Indian Journal of Dermatology, Venereology and Leprology, 79(5), 591–603. PMID 23974577
  7. Samrao A, Price VH, Zedek D, Mirmirani P. (2011). The "Fringe Sign" — a useful clinical finding in traction alopecia of the marginal hair line. Dermatology Online Journal, 17(11), 1. PMID 22136857
  8. Trost LB, Bergfeld WF, Calogeras E. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. Journal of the American Academy of Dermatology, 54(5), 824–844. PMID 16635664
  9. Dhurat R, Saraogi P. (2009). Hair evaluation methods: merits and demerits. International Journal of Trichology, 1(2), 108–119. PMID 20927232
  10. Wisuitiprot V, Ingkaninan K, Chakkavittumrong P, Wisuitiprot W, Neungchamnong N, Chantakul R, Waranuch N. (2022). Effects of Acanthus ebracteatus Vahl. extract and verbascoside on human dermal papilla and murine macrophage. Scientific Reports, 12(1), 1491. PMID 35087085

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR and MD Nutri Hair™, product lines of La Cañada Ventures, Inc. — physician-formulated since 2008 under the MD® mark (U.S. Reg. No. 4,471,494). She trained at Boston University School of Medicine and is board-certified in Obstetrics & Gynecology and in Anti-Aging Medicine (A4M).

MD® products are cosmetics and dietary supplements manufactured in FDA-registered, GMP-compliant facilities. "FDA-registered" describes the facility, not the product: MD® products are not FDA approved, and no cosmetic or dietary supplement is. Individual results vary. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

This article is for educational purposes and does not constitute medical advice. Central scalp thinning can reflect thyroid disease, iron deficiency, androgen excess or other medical conditions; consult your own physician for evaluation.

Explore more in our Hormonal & Life Stage Hair Loss series at mdhair.com/pages/hormonal-hair-loss